Breaking Finance News

Piper Jaffray Companies upgraded Inovio Pharmaceuticals Inc (NASDAQ:INO) to Overweight in a report released today.

Just yesterday Inovio Pharmaceuticals Inc (NASDAQ:INO) traded -2.33% lower at $8.08. The company’s 50-day moving average is $6.13 and its 200-day moving average is $6.65. The last stock close price is up -5.40% from the 200-day moving average, compared to the S&P 500 which has increased 0.03% over the same time. 1,212,718 shares of the stock were exchanged, down from an average trading volume of 1,593,870

Piper Jaffray Companies has upgraded Inovio Pharmaceuticals Inc (NASDAQ:INO) to Overweight in a report released on 6/8/2017.

See Chart Below

Inovio Pharmaceuticals Inc (NASDAQ:INO)

Inovio Pharmaceuticals Inc has a 52 week low of $5.28 and a 52 week high of $9.86 INO’s total market value is presently $0.

A total of 5 equity analysts have released a research note on INO. Two equity analysts rating the company a strong buy, three equity analysts rating the company a buy, zero equity analysts rating the company a hold, zero equity analysts rating the company a underperform, and finally zero equity analysts rating the company a sell with a one year target of $18.60.

More About Inovio Pharmaceuticals Inc (NASDAQ:INO)

Inovio Pharmaceuticals, Inc. (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company's DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases. It has completed, current or planned clinical programs of its SynCon immunotherapies for human papillomavirus (HPV)-caused pre-cancers and cancers, influenza, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus (HCV), hepatitis B virus (HBV), human immunodeficiency virus (HIV), Ebola, Middle East Respiratory Syndrome (MERS) and Zika virus. With its immunotherapy platform, as well as with its CELLECTRA electroporation delivery technology, it has a pipeline of pre-clinical and clinical stage products that have generated in vivo immune responses.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *